New drug targets Gene-Amplified breast cancers in early trial
NCT ID NCT07080619
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new drug called SC-101 in 120 people with advanced breast cancer (triple-negative or hormone-receptor-positive) that has a specific gene change called NECTIN4 amplification. Participants receive the drug once a week through an IV. The goal is to see if the drug can shrink tumors and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SC-101 (a drug given intravenously once weekly)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced breast cancers that have a specific gene change (NECTIN4 amplification).
- What could go wrong
- This is an early Phase IIa trial with only 120 people, so results may not confirm benefit. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+ BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Engineered immune cells take aim at Mesothelin-Positive tumors